Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Correction for Wolff et al., "Cell-Type-Dependent Regulation of mTORC1 by REDD1 and the Tumor Suppressors TSC1/TSC2 and LKB1 in Response to Hypoxia".

Wolff NC, Vega-Rubin-de-Celis S, Xie XJ, Castrillon DH, Kabbani W, Brugarolas J.

Mol Cell Biol. 2017 Jun 15;37(13). pii: e00224-17. doi: 10.1128/MCB.00224-17. Print 2017 Jul 1. No abstract available.

2.

High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma.

Wolff NC, Pavía-Jiménez A, Tcheuyap VT, Alexander S, Vishwanath M, Christie A, Xie XJ, Williams NS, Kapur P, Posner B, McKay RM, Brugarolas J.

Oncotarget. 2015 Jul 10;6(19):16951-62.

3.

REDD1/DDIT4-independent mTORC1 inhibition and apoptosis by glucocorticoids in thymocytes.

Wolff NC, McKay RM, Brugarolas J.

Mol Cancer Res. 2014 Jun;12(6):867-77. doi: 10.1158/1541-7786.MCR-13-0625. Epub 2014 Mar 10.

4.

A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma.

Sivanand S, Peña-Llopis S, Zhao H, Kucejova B, Spence P, Pavia-Jimenez A, Yamasaki T, McBride DJ, Gillen J, Wolff NC, Morlock L, Lotan Y, Raj GV, Sagalowsky A, Margulis V, Cadeddu JA, Ross MT, Bentley DR, Kabbani W, Xie XJ, Kapur P, Williams NS, Brugarolas J.

Sci Transl Med. 2012 Jun 6;4(137):137ra75. doi: 10.1126/scitranslmed.3003643.

5.

Regulation of TFEB and V-ATPases by mTORC1.

Peña-Llopis S, Vega-Rubin-de-Celis S, Schwartz JC, Wolff NC, Tran TA, Zou L, Xie XJ, Corey DR, Brugarolas J.

EMBO J. 2011 Jul 29;30(16):3242-58. doi: 10.1038/emboj.2011.257.

6.

Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma.

Kucejova B, Peña-Llopis S, Yamasaki T, Sivanand S, Tran TA, Alexander S, Wolff NC, Lotan Y, Xie XJ, Kabbani W, Kapur P, Brugarolas J.

Mol Cancer Res. 2011 Sep;9(9):1255-65. doi: 10.1158/1541-7786.MCR-11-0302. Epub 2011 Jul 28.

7.

Cell-type-dependent regulation of mTORC1 by REDD1 and the tumor suppressors TSC1/TSC2 and LKB1 in response to hypoxia.

Wolff NC, Vega-Rubin-de-Celis S, Xie XJ, Castrillon DH, Kabbani W, Brugarolas J.

Mol Cell Biol. 2011 May;31(9):1870-84. doi: 10.1128/MCB.01393-10. Epub 2011 Mar 7. Erratum in: Mol Cell Biol. 2017 Jun 15;37(13):.

8.

PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.

Wolff NC, Veach DR, Tong WP, Bornmann WG, Clarkson B, Ilaria RL Jr.

Blood. 2005 May 15;105(10):3995-4003. Epub 2005 Jan 18.

9.
10.

The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia.

Wolff NC, Richardson JA, Egorin M, Ilaria RL Jr.

Blood. 2003 Jun 15;101(12):5010-3. Epub 2003 Feb 20.

12.

Interference with the constitutive activation of ERK1 and ERK2 impairs EWS/FLI-1-dependent transformation.

Silvany RE, Eliazer S, Wolff NC, Ilaria RL Jr.

Oncogene. 2000 Sep 14;19(39):4523-30.

13.

Satiety effects of cholecystokinin and caerulein in rabbits.

Houpt TR, Anika SM, Wolff NC.

Am J Physiol. 1978 Jul;235(1):R23-8.

PMID:
677336

Supplemental Content

Loading ...
Support Center